← back to search

K Takenaka

Tokyo Medical and Dental University Hospital · JP
Area of research
Genetics · Hepatology
Research interest
Research interests include Inflammatory Bowel Disease, Hepatocellular Carcinoma Treatment and Prognosis, Gastrointestinal Bleeding Diagnosis and Treatment, and Hematopoietic Stem Cell Transplantation.
h-index
39
citations
5,379
works
200
NIH funding
primary concept
Medicine
email

Recent publications

Case Report of a Rapidly Progressive Indolent T-Cell Lymphoma of the Gastrointestinal Tract.
2027cited by 0position: contributordoi
Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Intestinal Research 2026cited by 9position: contributordoi
Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort.
2026cited by 0position: contributordoi
Efficacy and Rapid Response of Ustekinumab for Hospitalized Patients With Severe Ulcerative Colitis.
2026cited by 0position: contributordoi
Leucine-Rich Alpha-2 Glycoprotein Is an Accurate Serum Marker for Endoscopic and Histological Remission in Ulcerative Colitis
Inflammatory Intestinal Diseases 2026cited by 0position: contributordoi
Guidelines for endoscopic diagnosis and treatment of inflammatory bowel diseases.
2025cited by 4position: contributordoi
Evolving Role of Artificial Intelligence in Endoscopic Management of Inflammatory Bowel Disease: Diagnosis, Surveillance, and Assessment.
2025cited by 2position: contributordoi
Intestinal CD4<sup>-</sup>CD8αβ<sup>-</sup>TCRαβ<sup>+</sup> T cells function as tolerogenic antigen presenting cells in mice.
2025cited by 1position: contributordoi
Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn’s Disease
Inflammatory Intestinal Diseases 2025cited by 1position: contributordoi
Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor-Related Colitis
Digestion 2025cited by 0position: contributordoi
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Intestinal Research 2024cited by 16position: contributordoi
Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
Intestinal Research 2024cited by 12position: contributordoi
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.
2023cited by 27position: contributordoi
Systematic review of artificial intelligence-based image diagnosis for inflammatory bowel disease.
2022cited by 14position: contributordoi
Artificial intelligence for endoscopy in inflammatory bowel disease.
2022cited by 13position: contributordoi
Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
2021cited by 23position: contributordoi
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis.
2021cited by 18position: contributordoi
Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
2021cited by 16position: contributordoi
Colonic strictures mimicking Crohn's disease.
2021cited by 0position: contributordoi
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
2021cited by 0position: contributordoi
Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis
Gastroenterology 2020cited by 249position: contributordoi
Small Bowel Healing Detected by Endoscopy in Patients With Crohn's Disease After Treatment With Antibodies Against Tumor Necrosis Factor.
2020cited by 33position: contributordoi
Objective evaluation for treat to target in Crohn's disease.
2020cited by 17position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 23 papers (2020–2027)Ryuichi Okamoto · Institute of Science Tokyo13 papers (2021–2027)Ami Kawamoto · Tokyo Institute of Psychiatry12 papers (2021–2027) · 11 papers (2021–2027) · 11 papers (2020–2027)Kazuo Ohtsuka · University of Tokyo Hospital9 papers (2021–2027)Shuji Hibiya · Tokyo Medical and Dental University9 papers (2021–2027) · 9 papers (2021–2027) · 5 papers (2021–2024) · 5 papers (2021–2026) · 5 papers (2020–2021)Mamoru Watanabe · National Hospital Organization Takasaki Medical Center4 papers (2021–2022) · 4 papers (2020–2021)Akiko Tamura · Tokyo Medical and Dental University4 papers (2026–2027)Hiroshi Nakase · Sapporo Medical University1 papers (2025–2025)Mitsuhiro Fujishiro · The Institute of Medical Science, Asahi Life Foundation1 papers (2025–2025)Katsuyoshi Matsuoka · Toho University1 papers (2020–2020)Marietta Iacucci · University College Cork1 papers (2025–2025)Tadakazu Hisamatsu · Nippon Kayaku (Japan)1 papers (2025–2025)Motohiro Esaki · Kyushu University1 papers (2025–2025)